Qiagen N.V. (QGEN)
undefined
undefined%
At close: undefined
45.40
0.08%
After-hours Dec 13, 2024, 04:10 PM EST

Company Description

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide.

The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.

It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing.

In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables.

Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services.

It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers.

It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati.

The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

Qiagen N.V.
Qiagen N.V. logo
Country NL
IPO Date Jun 28, 1996
Industry Medical - Diagnostics & Research
Sector Healthcare
Employees 5,800
CEO Thierry Bernard

Contact Details

Address:
Hulsterweg 82
Venlo,
NL
Website https://www.qiagen.com

Stock Details

Ticker Symbol QGEN
Exchange NYSE
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001015820
CUSIP Number N72482123
ISIN Number NL0015001WM6
Employer ID 00-0000000
SIC Code 2836

Key Executives

Name Position
Thierry Bernard Chief Executive Officer, MD & Member of Management Board
Dr. Roland Sackers Chief Financial Officer, MD & Member of Management Board
Antonio Santos Senior Vice President & Head of Global Operations
Dr. Jonathan G. Sheldon Ph.D. Senior Vice President & Head of the QIAGEN Digital Insights Business Area
Dr. Thomas Schweins Senior Vice President of Life Science Business Area
Dr. Thomas Theuringer Senior Director & Head of External Communications
Fernando Beils Senior Vice President & Head of the Molecular Diagnostics Business Area
Jean-Pascal Viola Senior Vice President & Head of Corporate Strategy and Business Development
John Gilardi Vice President of Corporate Communications & Investor Relations
Stephany Foster Senior Vice President & Head of Human Resources

Latest SEC Filings

Date Type Title
Nov 08, 2024 SC 13G Statement of acquisition of beneficial ownership b...
Nov 08, 2024 6-K Filing
Nov 08, 2024 6-K Filing
Nov 08, 2024 6-K Filing
Nov 07, 2024 SC 13G Statement of acquisition of beneficial ownership b...
Oct 21, 2024 SC 13G Statement of acquisition of beneficial ownership b...
Sep 04, 2024 6-K Filing
Sep 03, 2024 6-K Filing
Aug 02, 2024 6-K Filing
Aug 02, 2024 6-K Filing